Last reviewed · How we verify

Evaluation of vaccines against flu

Assistance Publique - Hôpitaux de Paris · FDA-approved active Biologic

Evaluation of vaccines against flu is a vaccine Biologic drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Seasonal influenza prevention in adults and children, Influenza prevention in high-risk populations (elderly, immunocompromised, healthcare workers). Also known as: Evaluation of vaccines against flu in auto-imune diseases.

Flu vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection and severe disease.

Flu vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection and severe disease. Used for Seasonal influenza prevention in adults and children, Influenza prevention in high-risk populations (elderly, immunocompromised, healthcare workers).

At a glance

Generic nameEvaluation of vaccines against flu
Also known asEvaluation of vaccines against flu in auto-imune diseases
SponsorAssistance Publique - Hôpitaux de Paris
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Flu vaccines contain inactivated or attenuated influenza virus antigens that trigger both humoral (antibody) and cell-mediated immune responses. This allows the body to recognize and rapidly neutralize circulating influenza viruses upon exposure, reducing infection rates and disease severity. Multiple vaccine formulations exist (trivalent, quadrivalent, high-dose, adjuvanted) targeting different age groups and risk populations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Evaluation of vaccines against flu

What is Evaluation of vaccines against flu?

Evaluation of vaccines against flu is a vaccine drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Seasonal influenza prevention in adults and children, Influenza prevention in high-risk populations (elderly, immunocompromised, healthcare workers).

How does Evaluation of vaccines against flu work?

Flu vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection and severe disease.

What is Evaluation of vaccines against flu used for?

Evaluation of vaccines against flu is indicated for Seasonal influenza prevention in adults and children, Influenza prevention in high-risk populations (elderly, immunocompromised, healthcare workers).

Who makes Evaluation of vaccines against flu?

Evaluation of vaccines against flu is developed and marketed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is Evaluation of vaccines against flu also known as anything else?

Evaluation of vaccines against flu is also known as Evaluation of vaccines against flu in auto-imune diseases.

What drug class is Evaluation of vaccines against flu in?

Evaluation of vaccines against flu belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is Evaluation of vaccines against flu in?

Evaluation of vaccines against flu is FDA-approved (marketed).

What are the side effects of Evaluation of vaccines against flu?

Common side effects of Evaluation of vaccines against flu include Injection site soreness or erythema, Myalgia, Headache, Low-grade fever, Fatigue.

Related